GlassScriptPhysician profile
Jerry C Mclarty
NPI 1568444925
$1,291.22
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $732 · 2022: $485 · 2023: $41.10 · 2024: $33.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $74.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $74.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $431.44 | 2021-2022 | |
| Novo Nordisk INC | $319.27 | 2021-2022 | |
| Amarin Pharma, INC. | $94.63 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.43 | 2021-2022 | |
| Janssen Biotech, INC. | $58.05 | 2023-2024 | Tremfya, Stelara |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.66 | 2021-2022 | |
| Esperion Therapeutics, INC. | $46.29 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $34.99 | 2021 | |
| Merck Sharp & Dohme LLC | $32.21 | 2021 | |
| Pfizer INC. | $30.01 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $29.39 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.49 | 2022 | |
| Abbott Laboratories | $28.34 | 2021-2023 | Freestyle Libre 2 |
| Lilly USA, LLC | $24.27 | 2022 | |
| Genentech USA, INC. | $11.42 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $11.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Mclarty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.